

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/530,753
				Filing Date	(Int'l.) October 2, 2003
				First Named Inventor	Mariagrazia PIZZA
				Art Unit	1645
				Examiner Name	B. J. Gangle
Sheet	1	of	3	Attorney Docket Number	PAT051937-US-PCT

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document Country Code ³ -Number ³ -Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ⁴
	28.	1997-11-17-NM_shotgun.dbs and 1997-12-15-NM.dbs, located at <ftp://ftp.sanger.ac.uk/pub/pathogens/nm/old data/>				
	29.	Aasel et al. (1998). Abstract from the 11th International Pathogenic Neisseria Conference, Nice France, November 1-6, 1998. Pages 37-38.				
	30.	Bernfield L. et al. (September 2002). "Identification of a novel vaccine candidate for group B Neisseria meningitidis," Thirteenth International Pathogenic Neisseria Conference, Norwegian Institute of Public Health, Oslo, Norway, pages 116.				
	31.	Boslego et al. (1991). "Gonorrhea Vaccines," Chapter 17 In Vaccines and Immunotherapy, Cryz S.J. (Ed.), Pergamon Press: New York, NY, pp. 211-223.				
	32.	Cannon (1989). "Conserved Lipoproteins of Pathogenic Neisseria Species Bearing the H.8 Epitope: Lipid-Modified Azurin and H.8 Outer Membrane Protein," Clinical Microbiology Reviews, Vol. 2, Suppl., S1-S4.				
	33.	Cantini et al. (March 2006). "Solution Structure of the Immunodominant Domain of Protective Antigen GNA 1870 of Neisseria meningitidis," Journal of Biological Chemistry 281(11): 7220-7227.				
	34.	Declaration by Dr. Julian Parkhill dated June 12, 2008. 2 pages.				
	35.	Farley J. et al. (September 2002). "Characterization, cloning and expression of different subfamilies of the ORF 2086 gene from Neisseria meningitidis," Thirteenth International Pathogenic Neisseria Conference, Norwegian Institute of Public Health, Oslo, Norway, page, 124.				
	36.	Feavers et al. (2009). "Meningococcal protein antigens and vaccines," Vaccine 275:B42-B50.				
	37.	Fleischmann et al. (1995). "Whole-Genome Random Sequencing and Assembly of Haemophilus influenzae Rd," Science 269:496-501.				
	38.	Fletcher et al. (2004). "Vaccine Potential of the Neisseria meningitidis 2086 Lipoprotein," Infection and Immunity 72(4): 2088-2100.				

Substitute for form 1449/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/530,753		
		Filing Date	(Int.) October 2, 2003		
		First Named Inventor	Mariagrazia PIZZA		
		Art Unit	1645		
		Examiner Name	B. J. Gangle		
Sheet	2	of	3	Attorney Docket Number	PAT051937-US-PCT

39.	Fontana et al. (2002). "A genomic approach to identify vaccine candidates against gonococcus." Abstract from the 13th International Pathogenic Neisseria Conference, Oslo, Norway, September 1-6, 2002. Page 248.	
40.	Giuliani et al. (2006). "A universal vaccine for serogroup B meningococcus," PNAS 103(29):10834-10839.	
41.	Giuliani et al. (February 2005). "The Region Comprising Amino Acids 100 to 255 of Neisseria meningitidis Lipoprotein GNA 1870 Elicits Bactericidal Antibodies," Infection and Immunity 73(2): 1151-1160.	
42.	JCVI-CMR website showing Z2491 Sanger sequence (http://cmr.jcvi.org/tigr-scripts/CMR/shared/Genomes.cgi and links).	
43.	Masignani V. (March 17, 2003). "Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870," J. Exp. Med. 197(6):789-799.	
44.	Morley, S. et al. (December 12, 2001). "Vaccine prevention of meningococcal disease, coming soon?" Vaccine 20(5-6):666-687.	
45.	Nassif (2000). "A Furtive Pathogen Revealed," Science 287: 1767-1768.	
46.	Phase II clinical results for Novartis vaccine, October 9, 2008.	
47.	Post by Dr. Parkhill on BIOSCI/Bionet of May 8, 1998.	
48.	Progress through the Sanger Institute FTP server. FTP root at ftp.sanger.ac.uk .	
49.	PSORT analysis of 200 of the sequences disclosed in PCT/US99/09346 (i.e., the original application underlying the Patent; published as W099/057280).	
50.	PSORT analysis of SEQ ID NOs: 4 and 6, and of 'Contig295' 300mer.	
51.	PSORT prediction result for SEQ ID NO: 2.	
52.	Response to Communication, filed in EP Application No. 07075161.5. October 28th, 2009.	
53.	Rinaldo et al. (2009). "Vaccinology in the genome era", The Journal of Clinical Investigation, 119(9):2515-2525.	
54.	Romero et al. (1994). "Current status of Meningococcal group B vaccine candidates: capsular or noncapsular?" Clin. Microbiol. Rev. 7(4):559-575.	
55.	Sanger Centre's "Projects" website as of Dec. 10, 1997 as retrievable via http://web.archive.org .	
56.	Sequence for "Putative Lipoprotein [Neisseria Meningitidis Z2491]," NCBI Reference Sequence: YP_002342062.1, March 30, 2000.	
57.	Serruto et al. (2009). "Genome-based approaches to develop vaccines against bacterial pathogens," Vaccine 27:3245-3250.	
58.	Supplementary Declaration by Dr. Julian Parkhill, dated May 10, 2010.	
59.	Telford et al. (2003). "Genomic and Proteomics in Vaccine Design," in New Bacterial Vaccines, edited by Ellis et al. Kluwer Academic/Plenum Publishers, USA. Pages 1-11 (2 pages).	
60.	US Provisional Application No. 60/098,685, "Neisseria Spp, Polypeptide, Gene Sequence And Uses Thereof," filed September 01, 1998.	
61.	Welsch et al. (2004). "Protective Activity of Monoclonal Antibodies to Genome-Derived Neisserial Antigen 1870, a Neisseria meningitidis Candidate Vaccine," The Journal of Immunology 172: 5606-5615.	
62.	Zollinger (1997). "New and Improved Vaccines Against Meningococcal Disease" in New Generation Vaccines, 2nd Ed., edited by Levine et al., Marcel Dekker, New York. Pages 469-488.	
63.	Notice of Opposition against European Patent EP 1645631, granted on October 24, 2007. Opposition filed on July 23, 2008. 20 pages.	
64.	Patentees' Response to Opposition against European Patent EP 1645631, granted on October 24, 2007. 13 pages.	

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/530,753
				Filing Date	(Intl.) October 2, 2003
				First Named Inventor	Mariagrazia PIZZA
				Art Unit	1645
				Examiner Name	B. J. Gangle
Sheet	3	of	3	Attorney Docket Number	PAT051937-US-PCT

	65.	Supplemental Submission in Opposition against European Patent EP 1645631, granted on October 24, 2007. Opposition filed on May 25, 2010, 28 pages.	
--	-----	--	--

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.